Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

JPMorgan Checks In On Myriad Genetics Following 30% Rally

Courtesy of Benzinga.

Myriad Genetics, Inc.’s (NASDAQ: MYGN) strong run has caught investors attentions, however, JPMorgan analyst Tycho Peterson still doesn’t see the stock being able to offset a decline in the hereditary cancer business.

Peterson maintained his Underweight rating and $16 price target.

“While in the past, the esoteric LDT market was viewed as sitting at the nexus of the secular shift in healthcare towards personalized medicine, this vision has, in our view, run up against the reality that the LDT business model has a number of challenges, with many labs attempting to support a pharma model centered around heavy rep counts without the benefit of patent protection,” Peterson said.

Myriad Will Still Remain A Heavily Debated Stock As It Has Many Likeable Qualities

While Peterson expects the stock to fall to $16 – it trades around $25.60 per share – he noted the stock could still move in either direction.

“Myriad represents, in our view, a significant opportunity, given near-term catalysts that could drive the stock meaningfully higher or lower, with the setting of FY18 guidance during F4Q earnings (including forward expectations for hereditary cancer) being the most significant upcoming event post-UNH renewal,” he said.

However, “with its core business in (arguably) structural decline and pipeline that could be long on potential, but short on near-term financial impact, Myriad is not an easy company to value. While we believe the pipeline is intriguing, we do not believe that it can offset what we expect to be a continued steady decline in the core hereditary cancer business.”

Latest Ratings for MYGN

Date Firm Action From To
Feb 2017 Ladenburg Thalmann Upgrades Sell Neutral
Jan 2017 Deutsche Bank Initiates Coverage On Sell
Nov 2016 Stephens & Co. Downgrades Overweight Equal-Weight

View More Analyst Ratings for MYGN


View the Latest Analyst Ratings

Posted-In: JPMorgan Tycho PetersonAnalyst Color Reiteration Analyst Ratings


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!